Blockchain Registration Transaction Record

GeoVax Advances GEO-MVA Phase 3 Trial, Reports Q1 2026 Results

GeoVax Labs reports Q1 2026 financial results, highlights GEO-MVA Phase 3 trial progress for mpox/smallpox, and advances Gedeptin immuno-oncology platform with Emory license.

This news matters because GeoVax's GEO-MVA vaccine aims to diversify the global supply of MVA-based orthopoxvirus vaccines, reducing reliance on a single foreign supplier and bolstering public health preparedness against mpox and smallpox outbreaks. The expedited regulatory pathway could accelerate availability, addressing critical biodefense needs. Additionally, Gedeptin's potential to enhance checkpoint inhibitor therapy could improve outcomes for cancer patients with resistant tumors, addressing a significant unmet need in oncology.